Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide and dexamethasone (VRd) versus alone in patients with transplant-ineligible newly diagnosed multiple myeloma or for whom transplant is not planned as initial therapy: Analysis of minimal residual disease in the CEPHEUS trial Meeting Abstract
| Authors: | Zweegman, S.; Facon, T.; Hungria, V.; Bahlis, N. J.; Venner, C. P.; Braunstein, M.; Pour, L.; Tutusaus, J. M.; Basu, S.; Cohen, Y. C.; Matsumoto, M.; Suzuki, K.; Hulin, C.; Grosicki, S.; Legiec, W. M.; Beksac, M.; Maiolino, A.; Takamatsu, H.; Perrot, A.; Turgut, M.; Liu, W.; Wang, J.; Chastain, K.; Vermeulen, J.; Krevvata, M.; Lopez-Masi, L.; Carey, J.; Rowe, M.; Carson, R.; Usmani, S. Z. |
| Abstract Title: | Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide and dexamethasone (VRd) versus alone in patients with transplant-ineligible newly diagnosed multiple myeloma or for whom transplant is not planned as initial therapy: Analysis of minimal residual disease in the CEPHEUS trial |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 362 |
| End Page: | 364 |
| Language: | English |
| ACCESSION: | WOS:001412359600012 |
| DOI: | 10.1182/blood-2024-200871 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
